Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases

By N. Ampel. 2007

3,909 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study (2013, background): “simiae was traditionally thought to be confined to the Southern USA, Cuba and Israel [7], but in this study we demonstrate that this species has a global distribution (except Asia),”
A Novel Gene, erm(41), Confers Inducible Macrolide Resistance to Clinical Isolates of Mycobacterium abscessus but Is Absent from Mycobacterium chelonae (2009, background): “, clarithromycin and azithromycin), and these agents are important components in the treatment of RGM infections (11, 12, 17, 19, 43).”
Rapid Detection of Mycobacterium tuberculosis and Rifampin Resistance by Use of On-Demand, Near-Patient Technology (2009, methodology): “We studied assay specificity using unprocessed sputum containing 10(6) CFU/ml of 20 NTM species, including the 16 NTM commonly described as causing human disease (18).”
Aminoglycosides: An Overview. (2016, methodology): “Similar to treatment of MDR-TB, combination therapy for patients with fibrocavitary, severe nodular/ bronchiectatic or macrolide-resistant lung disease because of the M. avium complex generally includes amikacin or streptomycin (Griffith et al. 2007).”
Epidemiology of Human Pulmonary Infection with Non-Tuberculous Mycobacteria: A Review (2014, background): “The diagnosis comprises three components, including microbiologic, radiographic, and clinical criteria (6).”